Skip to main content
. 2016 Nov 3;4(4):310–319. doi: 10.14218/JCTH.2016.00027

Table 2a. Comparison of treatment guidelines for treatment-naïve patients infected with HCV genotype 2.

AASLD/IDSA EASL WHO# APASL

  • Sofosbuvir/velapatasvir (I-A)

  • Sofosbuvir/daclatasvir (IIa-B)a

  • PegIFN-α/RBV/sofosbuvir (B1)

  • Sofosbuvir/RBVa (A1)

  • Sofosbuvir/daclatasvir (B1)

  • Sofosbuvir/RBVa

Alternative

  • Sofosbuvir/daclatasvir

  • Sofosbuvir/RBV (A1)

  • Sofosbuvir/daclatasvir (24 weeks)* (B1)

  • Sofosbuvir/ledipasvir* (B1)

  • Sofosbuvir/velpatasvir* (B1)
*

For RBV intolerant patients;

#

All regimens: strong recommendation, low quality of evidence.

a

16–24 weeks in patients with cirrhosis.

Abbreviations: PegIFN, Pegylated interferon; RBV, Ribavirin.

All treatment courses are 12 weeks unless indicated otherwise.